Payment overview · 2025
General Payments
$1,866.02
116 reported records · 23 companies
Healthcare provider profile · identity verified
Ronald B Scott, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEW ALBANY, MS · NPI 1790751469
Verified facts
What the public records show
CMS Open Payments records show Ronald B Scott, D.O. received $1,866.02 in general payments during 2025 across 116 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Farxiga, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $259.33 | 13.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $249.06 | 13.3% | 23 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $243.00 | 13.0% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $237.00 | 12.7% | 20 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $157.66 | 8.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $138.99 | 7.5% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $76.29 | 4.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $71.86 | 3.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.13 | 3.1% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $47.63 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.99 | 1.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.16 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.62 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.96 | 1.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.25 | 1.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.46 | 1.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.68 | 1.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.16 | 1.2% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.67 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.38 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.01 | 1.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.52 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.21 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,866.02 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $243.00 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $237.00 | 20 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $158.78 | 11 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $157.66 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $141.92 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.31 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.89 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.19 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $90.24 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.79 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $84.19 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $73.62 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.70 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.13 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.13 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $47.63 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.62 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $9.47 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 326 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 246 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 132 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 273 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 159 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
132 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
246 | 49 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
159 | 32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
257 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
273 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
326 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1037 | 209 |
| Pantoprazole Sodium | Pantoprazole Sodium | 790 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 773 | 166 |
| Gabapentin | Gabapentin | 766 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 765 | 148 |
| Furosemide | Furosemide | 740 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 699 | 150 |
| Lisinopril | Lisinopril | 671 | 133 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 604 | 139 |
| Losartan Potassium | Losartan Potassium | 563 | 132 |
| Carvedilol | Carvedilol | 557 | 121 |
| Potassium Chloride | Potassium Chloride | 553 | 96 |
| Omeprazole | Omeprazole | 481 | 117 |
| Famotidine | Famotidine | 472 | 101 |
| Sertraline Hcl | Sertraline Hcl | 434 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 407 | 98 |
| Trazodone Hcl | Trazodone Hcl | 375 | 74 |
| Metformin Hcl | Metformin Hcl | 371 | 91 |
| Donepezil Hcl | Donepezil Hcl | 369 | 58 |
| Buspirone Hcl | Buspirone Hcl | 358 | 60 |
| Meloxicam | Meloxicam | 341 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 337 | 73 |
| Eliquis | Apixaban | 326 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 71 |
| Montelukast Sodium | Montelukast Sodium | 295 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 292 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 283 | 63 |
| Ozempic | Semaglutide | 273 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 257 | 50 |
| Jardiance | Empagliflozin | 257 | 56 |
| Farxiga | Dapagliflozin Propanediol | 246 | 49 |
| Clonazepam | Clonazepam | 229 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 223 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 219 | 73 |
| Tramadol Hcl | Tramadol Hcl | 216 | 66 |
| Memantine Hcl | Memantine Hcl | 215 | 31 |
| Pregabalin | Pregabalin | 209 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 206 | 87 |
| Divalproex Sodium | Divalproex Sodium | 202 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 185 | 37 |
| Allopurinol | Allopurinol | 182 | 32 |
| Ezetimibe | Ezetimibe | 181 | 41 |
| Lorazepam | Lorazepam | 179 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 174 | 41 |
| Metformin Hcl Er | Metformin Hcl | 174 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 54 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 161 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 159 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 151 | 33 |
| Ibuprofen | Ibuprofen | 149 | 37 |
| Mirtazapine | Mirtazapine | 145 | 38 |
| Simvastatin | Simvastatin | 145 | 30 |
| Spironolactone | Spironolactone | 144 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 141 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 139 | 60 |
| Baclofen | Baclofen | 136 | 18 |
| Linzess | Linaclotide | 132 | 39 |
| Bupropion Xl | Bupropion Hcl | 131 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 34 |
| Prednisone | Prednisone | 131 | 70 |
| Tresiba Flextouch U-200 | Insulin Degludec | 130 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 127 | 27 |
| Topiramate | Topiramate | 119 | 27 |
| Methotrexate | Methotrexate Sodium | 117 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 26 |
| Lovastatin | Lovastatin | 109 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 73 |
| Olanzapine | Olanzapine | 107 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 35 |
| Xarelto | Rivaroxaban | 105 | 22 |
| Fenofibrate | Fenofibrate | 101 | 22 |
| Cefdinir | Cefdinir | 98 | 81 |
| Celecoxib | Celecoxib | 98 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 19 |
| Cephalexin | Cephalexin | 97 | 66 |
| Fluconazole | Fluconazole | 96 | 54 |
| Warfarin Sodium | Warfarin Sodium | 95 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 93 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 93 | 16 |
| Alprazolam | Alprazolam | 91 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 91 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 90 | 28 |
| Promethazine Hcl | Promethazine Hcl | 89 | 21 |
| Torsemide | Torsemide | 88 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 21 |
| Januvia | Sitagliptin Phosphate | 85 | 14 |
| Mounjaro | Tirzepatide | 85 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 17 |
| Levetiracetam | Levetiracetam | 81 | 16 |
| Clonidine Hcl | Clonidine Hcl | 80 | 21 |
| Estradiol | Estradiol | 79 | 17 |
| Mupirocin | Mupirocin | 79 | 63 |
| Myrbetriq | Mirabegron | 79 | 13 |
| Finasteride | Finasteride | 77 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 76 | 33 |
| Chlorthalidone | Chlorthalidone | 74 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 21 |
| Dapagliflozin | Dapagliflozin Propanediol | 73 | 23 |
| Fentanyl | Fentanyl | 73 | 13 |
| Midodrine Hcl | Midodrine Hcl | 73 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 36 |
| Sevelamer Carbonate | Sevelamer Carbonate | 71 | suppressed |
| Trulicity | Dulaglutide | 71 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 70 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 70 | 23 |
| Alendronate Sodium | Alendronate Sodium | 69 | 12 |
| Propranolol Hcl | Propranolol Hcl | 69 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 68 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | 12 |
| Ondansetron Odt | Ondansetron | 67 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 18 |
| Azithromycin | Azithromycin | 65 | 57 |
| Belsomra | Suvorexant | 65 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 65 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 64 | 11 |
| Valacyclovir | Valacyclovir Hcl | 64 | 17 |
| Atenolol | Atenolol | 63 | 12 |
| Bumetanide | Bumetanide | 63 | 17 |
| Sucralfate | Sucralfate | 63 | 13 |
| Temazepam | Temazepam | 63 | 14 |
| Glimepiride | Glimepiride | 62 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 62 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 61 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Novolog Flexpen | Insulin Aspart | 60 | 17 |
| Methocarbamol | Methocarbamol | 58 | 33 |
| Naproxen | Naproxen | 55 | 19 |
| Acyclovir | Acyclovir | 54 | 15 |
| Meclizine Hcl | Meclizine Hcl | 54 | 28 |
| Novolog | Insulin Aspart | 54 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 53 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Lansoprazole | Lansoprazole | 52 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 36 |
| Latanoprost | Latanoprost | 51 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 15 |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Tradjenta | Linagliptin | 50 | suppressed |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Glipizide | Glipizide | 49 | suppressed |
| Humalog | Insulin Lispro | 47 | 13 |
| Levofloxacin | Levofloxacin | 47 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | 13 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 22 |
| Valsartan | Valsartan | 44 | 12 |
| Nystatin | Nystatin | 43 | 32 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 40 | 14 |
| Eszopiclone | Eszopiclone | 40 | 11 |
| Haloperidol | Haloperidol | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 25 |
| Methylprednisolone | Methylprednisolone | 38 | 35 |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Zaleplon | Zaleplon | 37 | 11 |
| Brilinta | Ticagrelor | 36 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 36 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 25 |
| Ceftriaxone | Ceftriaxone Sodium | 35 | 19 |
| Colchicine | Colchicine | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Febuxostat | Febuxostat | 35 | suppressed |
| Insulin Lispro | Insulin Lispro | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 22 |
| Dilt-Xr | Diltiazem Hcl | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Anastrozole | Anastrozole | 32 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Lactulose | Lactulose | 31 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Vraylar | Cariprazine Hcl | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 23 |
| Nystop | Nystatin | 29 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Acetazolamide | Acetazolamide | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Letrozole | Letrozole | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 26 | 18 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Cyclosporine | Cyclosporine | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Perphenazine | Perphenazine | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 14 |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Cefprozil | Cefprozil | 20 | 16 |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 19 | 13 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Wegovy | Semaglutide | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 16 | suppressed |
| Caplyta | Lumateperone Tosylate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fetzima | Levomilnacipran Hcl | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,866.02 · 116 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE, FREESTYLE LIBRE 3, IBSRELA, Jornay PM, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, Qelbree, RECORLEV, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND, Zunveyl | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error